Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
BackgroundLebanon is undergoing substantial demographic and social change, with older adults comprising approximately 10% of the population.
Why it matters
This study describes a new group of 1,871 people in Lebanon, including participants in a late-life learning program, who will be followed over time to study cognitive aging and dementia risk. No results on whether learning affects dementia risk are reported yet, because the study is still ongoing.
-
Higher education (OR = 1.23, SE = 0.05, 95% CI = [1.10, 1.36], p < 0.001), female sex (OR = 1.30, SE = 0.09, 95% CI = [1.10, 1.55], p = 0.003), and lower age (OR = 0.67, SE = 0.04, 95% CI = [0.61, 0.73], p < 0.001) were associated with increased odds of SuperAger status.
Why it matters
This study found that absence of hypertension, lower depressive symptoms, higher fruit and vegetable intake, and greater social activity were modestly associated with being a SuperAger. These factors do not fully explain exceptional cognitive ageing, and the study does not show that they prevent or cure Alzheimer's disease.
-
ObjectivesSubjective word-finding complaints (SWFC) are among the most frequent cognitive complaints in cognitively unimpaired older adults (CU).
Why it matters
This study developed and evaluated a questionnaire for subjective word-finding complaints in older adults and found six distinct factors and some demographic and clinical correlates. It is about measuring a symptom, not about treating, curing, or preventing Alzheimer's disease.
-
These findings show that model-based, adaptive assessments can support high-frequency, remote detection and scalable longitudinal monitoring of early memory decline, providing a new way to assess memory decline trajectories in healthy aging and dementia.
Why it matters
This study shows that model-based, adaptive digital assessments can support high-frequency remote monitoring of early memory decline in healthy aging and mild cognitive impairment. It is a monitoring tool, not a treatment, cure, or prevention for Alzheimer's disease.
-
16/100
BackgroundThe 10 Year Health Plan for England indicates governmental intention to shift care from hospital to community.
Why it matters
This survey of general practitioners in England explored current dementia diagnosis and care, and expectations about future disease-modifying treatments and biomarker tests. It is about health services and planning, not about treating, curing, or preventing Alzheimer's disease.
-
ObjectiveTo determine whether a multi-trait polygenic profile for dementia is associated with dementia- and disability-free survival in middle-aged and older adults.
Why it matters
This study found that adverse polygenic profiles for dementia were associated with higher risk of dementia, disability, or death in a large population. It supports polygenic profiling for risk stratification but does not test any treatment, cure, or prevention.
-
Large language models (LLMs) are increasingly used for qualitative analysis, but strong language performance does not guarantee strong interpretation when meaning depends on method and context.
Why it matters
This study developed and evaluated a workflow for using large language models to analyze interviews about fear of dementia. It is about research methods for qualitative data analysis, not about treating, curing, or preventing Alzheimer's disease.
-
BackgroundDeep-learning models predict mild cognitive impairment (MCI)-to-Alzheimers disease (AD) conversion from structural MRI with high accuracy.
Why it matters
This study tested a deep-learning model that predicts conversion from mild cognitive impairment to Alzheimer's disease using MRI, and found its risk scores tracked brain atrophy, cognitive decline, and functional connectivity changes. It is a validation of a prediction model, not a treatment, cure, or prevention.
-
In female participants, higher education was associated with lower Thal amyloid phase, diffuse plaques, neuritic plaques, and Braak stage ({beta} range, -0.097 to -0.071; qFDR<.026); none was significant among male participants.
Why it matters
In this autopsy study, higher education was linked to lower Alzheimer's disease neuropathology in women but not men, and to a weaker link between tau pathology and cognition in women. This suggests education may relate differently to Alzheimer's brain changes and thinking in women and men, but it does not show that education prevents or cures the disease.
-
BACKGROUNDSubjective cognitive decline (SCD) may precede mild cognitive impairment (MCI), but not all individuals with SCD progress to MCI.
Why it matters
This study used machine learning on MRI and other data to predict which people with subjective cognitive decline will develop mild cognitive impairment. MRI features, especially regional white matter hyperintensity and gray matter volumes, improved prediction more than cognitive tests at 3, 4, and 5 years, but this is a prediction tool, not a treatment or cure.
-
O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=113 SRC="FIGDIR/small/26361997v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@1dac0d9org.highwire.dtl.DTLVardef@aaf8f2org.highwire.dtl.DTLVardef@be10a1org.highwire.dtl.DTLVardef@35c7be_HPS_FORMAT_FIGEXP M_FIG C_FIG BACKGROUNDThe effect of neurovascular health on cardiovascular outcomes is not well-known.
Why it matters
This study found that a higher burden of cerebral small vessel disease markers on brain MRI was linked to higher risk of cardiovascular events and all-cause mortality, with a dose-response relationship for mortality and increased stroke risk but no significant association with heart attack. It concerns vascular risk prediction and does not test any treatment, cure or prevention for Alzheimer's disease.
-
The Middle East and North Africa (MENA) region is projected to experience the fastest growth in dementia burden globally, yet population-based data on cognitive aging remain scarce.
Why it matters
This study adapted and evaluated a comprehensive cognitive assessment battery in an Arabic-speaking population in Lebanon and found good to excellent model fit. It establishes research infrastructure for cognitive aging and does not test any treatment, cure or prevention.
-
Prior work suggests that perceived value may shape online support use, yet practical and trust-related barriers may still impede uptake even when beliefs are favorable.
Why it matters
This survey found that about two-thirds of informal dementia caregivers used online peer support in the past three months, with use linked to belief in its value, eHealth literacy, willingness to use an experience-search tool and caregiving stress. It concerns caregiver support and does not test any treatment, cure or prevention.
-
BackgroundFear of dementia (FoD) can shape psychological well-being and responses to perceived cognitive change.
Why it matters
This qualitative study explored fear of dementia, coping and support needs among middle-aged and older adults in China, finding that preferred interventions were accessible, low-burden and professionally guided. It concerns psychosocial support and does not test any treatment, cure or prevention.
-
BackgroundThe prevalence and pattern of secondary causes of first-onset psychosis (FEP) in Asian populations are understudied.
Why it matters
This retrospective study of first-episode psychosis in Hong Kong found that substance use was the most common secondary cause, and that early-onset dementia was among the conditions uncovered by workup in some patients. It concerns causes of psychosis and does not test any treatment, cure or prevention for Alzheimer's disease.
-
16/100
ObjectiveRegression-based normative approaches are widely used in neuropsychology but often rely on score transformations to satisfy model assumptions.
Why it matters
This study compared two methods for developing cognitive test norms and found high agreement between them, with only modest downstream differences in clinical classification. It is about neuropsychological testing methods and does not test any treatment, cure or prevention.
-
BackgroundPhenotypic age acceleration (PhenoAgeAccel), derived from PhenoAge, and MetaboHealth are composite exposures of biological ageing and metabolic health associated with dementia-related outcomes.
Why it matters
This study used genetic methods to examine whether biological aging and metabolic health have causal roles in dementia, and linked these measures to dementia outcomes and cognition in longitudinal data. It identifies possible risk factors and does not test any treatment, cure or prevention.
-
Artificial intelligence applied to routine electrocardiograms (ECGs) has largely focused on detecting existing disease or predicting individual cardiovascular outcomes.
Why it matters
This study found that a model using routine ECG data could predict future diagnoses across organ systems, with the highest discrimination for dementia. It is a prediction feasibility study requiring external validation and does not test any treatment, cure or prevention.
-
BACKGROUNDPeople with type 2 diabetes mellitus (T2DM) are at higher risk of cerebral small vessel disease and left ventricular hypertrophy (LVH), potentially contributing to cognitive decline and dementia.
Why it matters
In this cohort of people with type 2 diabetes, left ventricular hypertrophy was found to cause less brain atrophy over two years with no effect on cognitive decline. The authors suggest guideline-directed left ventricular hypertrophy therapies such as beta-blockers may have neuroprotective effects, but this was not a treatment trial for Alzheimer's disease.
-
16/100
ImportanceThe ASPREE randomized trial found no overall benefit of low-dose aspirin for disability-free survival among older adults.
Why it matters
In this post hoc analysis of the ASPREE trial, low-dose aspirin was associated with lower risk of loss of disability-free survival among US Black and Hispanic participants, with the largest benefit in the greatest predicted-benefit group. This is a subgroup analysis of a trial that found no overall benefit, so it does not establish aspirin as a way to prevent dementia.
-
Early identification of cognitive impairment remains challenging in settings where comprehensive cognitive and clinical assessments are not available.
Why it matters
In this proof-of-concept study, combining cognitive, acoustic and linguistic features classified cognitively unimpaired people from those with amnestic mild cognitive impairment or early Alzheimer's disease better than either alone. It supports development of screening tools, not treatment, cure or prevention.
-
INTRODUCTIONNeurodegenerative research identifies biomarkers to confirm presence of disease and inform about risk for clinical symptoms.
Why it matters
This survey of CADASIL research participants found high interest in receiving individual research results, with respondents rating reasons to return results higher than Alzheimer's disease counterparts on most items. It addresses research ethics and communication, not treating, curing or preventing Alzheimer's disease.
-
In the fully adjusted Cox model, baseline statin exposure was associated with a lower risk of incident AMI (HR, 0.805; 95% CI, 0.731-0.887).
Why it matters
This cohort study found that baseline statin exposure was associated with a lower incidence of acute myocardial infarction in adults aged 75 and older without prior cardiovascular disease. It concerns heart attack risk, not Alzheimer's disease treatment, cure or prevention.
-
Persistent racial disparities in dementia raise concerns regarding the validity and generalizability of existing prognostic models across diverse populations.
Why it matters
Using NACC data, this analysis found that random survival forest models predicted dementia risk better than Cox models across racial groups, and that adding resting heart rate modestly improved prediction. It is about risk prediction tools, not treating, curing or preventing Alzheimer's disease.
-
The feasibility criteria of >80% was met.
Why it matters
In this small single-arm pilot in brain cancer patients with mild cognitive impairment, virtual reality cognitive training met feasibility criteria and some cognitive test scores improved significantly, while the TM-A/B improvement was not statistically significant. The small sample size and single-arm design mean these preliminary results cannot show that this training treats or prevents Alzheimer's disease.
From across this topic
10 of the 7,967 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Alzheimer's Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting
- Grocery Store Density and Food Waste
- Associations of dietary choline intake with risk of incident dementia and with cognitive performance: the Kuopio Ischaemic Heart Disease Risk Factor Study
- The Association of Ambient Air Pollution With Dynamic Transitions of Cataract and Dementia: A UK Biobank Study
- Prevalence of Depression in Patients With Mild Cognitive Impairment: A Systematic Review and Meta-analysis
- MRI hippocampal volumes and memory function before and after temporal lobectomy
- Impact of regional inequalities in long-term care on health spending: evidence from dementia patients in France
- The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function
- Caregiver burden in end-of-life care: advanced cancer and final stage of dementia
- Framingham stroke risk profile and lowered cognitive performance